[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605467":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":24,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":24,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":24,"overallStatus":76,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Shalamar Institute of Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crisaborole 2% Ointment","ACTIVE_COMPARATOR","Twice daily application to affected areas for 28 days",[13],"Drug: Crisaborole 2%",{"label":15,"type":10,"description":11,"interventionNames":16},"Tacrolimus 0.1% Ointment",[17],"Drug: Tacrolimus 0.1%",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Crisaborole 2%","Apply thin layer to affected skin daily for 28 days.",[9],null,{"type":20,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"Tacrolimus 0.1%",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Kheziema Maryum","CONTACT","0310-4999940","doc.kheziemamaryum@gmail.com",[35],{"facility":36,"status":24,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Shalamar Hospital Lahore","Lahore","Punjab Province","54000","Pakistan","PK",{"type":43,"coordinates":44},"Point",[45,46],74.35071,31.558,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":24,"email":52},"Shalamar Hospital Lahore Shalamar Hospital Lahore","(042)111205205","info@sihs.org.pk",{"type":54,"investigatorFullName":30,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100605467","phase-3-crisaborole-2-versus-tacrolimus-01-in-children-with-mild-to-moderate-atopic-dermatitis-100605467",false,"NCT07162896","Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n* Age 2-18 years Both genders Clinically diagnosed mild to moderate atopic dermatitis Body surface area (BSA) \\\u003C30%\n\nExclusion Criteria:\n\nActive viral, bacterial, or fungal skin infection at the treatment site\n\nRecent use of topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, or immunosuppressive medication within past 2 weeks\n\nKnown hypersensitivity to study medications or components\n\nChronic inflammatory conditions (e.g., psoriasis and seborrheic dermatitis) that may interfere with evaluation","ALL","2 Years","18 Years",{"count":67,"type":68},66,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis. A total of 66 participants will be randomized (1:1) to receive either Crisaborole or Tacrolimus, applied twice daily to affected areas for 28 days. Primary endpoint is proportion of participants achieving Investigator's Static Global Assessment (ISGA) success (clear\u002Falmost clear with ≥2-point improvement from baseline) at Day 28. Safety assessments include adverse events and local application site reactions.",[74,75],"Atopic Dermatitis","Atopic Dermatitis (AD)","NOT_YET_RECRUITING","2025-08-31",{"date":79,"type":80},"2025-09-09","ACTUAL",{"date":82,"type":68},"2026-06",{"date":84,"type":68},"2027-06",{"name":5,"class":6},1]